ES2942329T3 - Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida - Google Patents

Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida Download PDF

Info

Publication number
ES2942329T3
ES2942329T3 ES16783764T ES16783764T ES2942329T3 ES 2942329 T3 ES2942329 T3 ES 2942329T3 ES 16783764 T ES16783764 T ES 16783764T ES 16783764 T ES16783764 T ES 16783764T ES 2942329 T3 ES2942329 T3 ES 2942329T3
Authority
ES
Spain
Prior art keywords
meropenem
compound
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16783764T
Other languages
English (en)
Spanish (es)
Inventor
David Griffith
Michael Dudley
Jeffrey Loutit
Olga Lomovskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57144340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2942329(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Application granted granted Critical
Publication of ES2942329T3 publication Critical patent/ES2942329T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16783764T 2015-04-24 2016-04-20 Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida Active ES2942329T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152668P 2015-04-24 2015-04-24
PCT/US2016/028437 WO2016172208A1 (en) 2015-04-24 2016-04-20 Methods of treating bacterial infections

Publications (1)

Publication Number Publication Date
ES2942329T3 true ES2942329T3 (es) 2023-05-31

Family

ID=57144340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16783764T Active ES2942329T3 (es) 2015-04-24 2016-04-20 Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida

Country Status (8)

Country Link
US (2) US20160339045A1 (enExample)
EP (1) EP3285776B1 (enExample)
JP (2) JP6945452B2 (enExample)
CN (2) CN112755039A (enExample)
AU (1) AU2016252555A1 (enExample)
CA (1) CA2982911C (enExample)
ES (1) ES2942329T3 (enExample)
WO (1) WO2016172208A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US12478606B2 (en) * 2017-01-09 2025-11-25 Melinta Subsidiary Corp. Methods of treating bacterial infections
AU2018345317B2 (en) * 2017-10-03 2024-10-24 Melinta Therapeutics, Inc. Methods of treating bacterial infections
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
CN116098993B (zh) * 2022-11-17 2024-10-25 中国农业科学院特产研究所 一种狐、貉肺炎三联灭活疫苗及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2016252555A1 (en) 2017-11-09
US20160339045A1 (en) 2016-11-24
CN112755039A (zh) 2021-05-07
WO2016172208A1 (en) 2016-10-27
JP2021143196A (ja) 2021-09-24
EP3285776A4 (en) 2019-01-23
EP3285776A1 (en) 2018-02-28
HK1249432A1 (en) 2018-11-02
US20190105337A1 (en) 2019-04-11
EP3285776B1 (en) 2022-12-21
CA2982911C (en) 2023-10-03
CA2982911A1 (en) 2016-10-27
JP2018513188A (ja) 2018-05-24
JP7245289B2 (ja) 2023-03-23
JP6945452B2 (ja) 2021-10-06
CN107530364A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
JP7245289B2 (ja) 細菌感染症の処置方法
US11007206B2 (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2985626T3 (es) Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
ES2979266T3 (es) Procedimientos de tratamiento de infecciones bacterianas con una combinación de vaborbactam y meropenem
ES3036963T3 (en) Boronic acid derivatives and therapeutic uses thereof
ES3026983T3 (en) Ceftolozane antibiotic compositions
EP3849562B1 (en) Combination compositions comprising a beta-lactamase inhibitor
BRPI0612447A2 (pt) composição antibiótica de dose fixa, processo para a preparação de um produto de combinação antibiótica de dose fixa, processo para a preparação de uma injeção lìquida e usos de pó seco para injeção e injeção lìquida
HK40051777A (en) Methods of treating bacterial infections
HK1249432B (en) Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function
WO2014071155A1 (en) Therapeutic uses of tigemonam and carumonam
HK40097685A (en) Methods of treating bacterial infections with vaborbactam and meropenem
WO2024128238A1 (ja) 細菌感染症の治療剤
HK40018408B (en) Methods of treating bacterial infections with a combination of vaborbactam and meropenem
HK40018408A (en) Methods of treating bacterial infections with a combination of vaborbactam and meropenem